FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126149503> ?p ?o ?g. }

• W3126149503 endingPage "209" @default.
• W3126149503 startingPage "203" @default.
• W3126149503 abstract "Background and purpose This study explored the feasibility of safely combining prexasertib, with cisplatin-radiotherapy (Part A) or cetuximab-radiotherapy (Part B) in patients with previously untreated, locoregionally advanced head and neck squamous cell carcinoma (HNSCC). Materials and methods Escalating doses of prexasertib were administered in each combination using a modified Time-to-Event Continual Reassessment Method. Pharmacokinetic (PK) analysis was performed using standard non-compartmental methods of analysis. Antitumor activity was evaluated using RECIST version 1.1. Results In Part A, 7 patients received 20 mg/m2 prexasertib and cisplatin-radiotherapy. This dose exceeded the maximum tolerated dose (MTD); no other prexasertib dose was assessed. In Part B, 18 patients received prexasertib (20–40 mg/m2) and cetuximab-radiotherapy. The 30 mg/m2 dose of prexasertib was determined as the MTD. Febrile neutropenia was the dose-limiting toxicity in each arm. Most common treatment-emergent adverse events with both combinations were neutropenia, thrombocytopenia, dysphagia, stomatitis, dry mouth, anemia, radiation skin injury [reported term radiation dermatitis], and nausea. PK of prexasertib was consistent with previously published data following prexasertib monotherapy. Overall response rate in Parts A and B was 71.4% and 83.3%, respectively. The small number of patients and follow-up limits the interpretation of efficacy data. Conclusion This study did not establish a safe dose of cisplatin-radiotherapy. However, it demonstrates the proof-of-principle that prexasertib could be safely combined with cetuximab-radiotherapy. These data will provide the basis to leverage the potential radio-sensitization properties of a CHK1 inhibitor in combination with radiation or other targeted agents in a variety of therapeutic settings." @default.
• W3126149503 created "2021-02-15" @default.
• W3126149503 creator A5013341404 @default.
• W3126149503 creator A5014829112 @default.
• W3126149503 creator A5017334285 @default.
• W3126149503 creator A5028065894 @default.
• W3126149503 creator A5035724058 @default.
• W3126149503 creator A5039160380 @default.
• W3126149503 creator A5044080421 @default.
• W3126149503 creator A5045285437 @default.
• W3126149503 creator A5045899822 @default.
• W3126149503 creator A5055221542 @default.
• W3126149503 creator A5061545133 @default.
• W3126149503 creator A5065471639 @default.
• W3126149503 creator A5074756797 @default.
• W3126149503 creator A5076699095 @default.
• W3126149503 date "2021-04-01" @default.
• W3126149503 modified "2023-09-26" @default.
• W3126149503 title "A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma" @default.
• W3126149503 cites W1594035260 @default.
• W3126149503 cites W1979803759 @default.
• W3126149503 cites W2006864140 @default.
• W3126149503 cites W2008329039 @default.
• W3126149503 cites W2018678771 @default.
• W3126149503 cites W2019607817 @default.
• W3126149503 cites W2069491777 @default.
• W3126149503 cites W2112845420 @default.
• W3126149503 cites W2120068217 @default.
• W3126149503 cites W2122642455 @default.
• W3126149503 cites W2140990686 @default.
• W3126149503 cites W2145078756 @default.
• W3126149503 cites W2150405633 @default.
• W3126149503 cites W2155384808 @default.
• W3126149503 cites W2162287242 @default.
• W3126149503 cites W2338722087 @default.
• W3126149503 cites W2580602635 @default.
• W3126149503 cites W2798232370 @default.
• W3126149503 cites W2890083017 @default.
• W3126149503 cites W2897182604 @default.
• W3126149503 cites W2901263658 @default.
• W3126149503 cites W3022157481 @default.
• W3126149503 cites W4241699770 @default.
• W3126149503 doi "https://doi.org/10.1016/j.radonc.2021.01.032" @default.
• W3126149503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33577866" @default.
• W3126149503 hasPublicationYear "2021" @default.
• W3126149503 type Work @default.
• W3126149503 sameAs 3126149503 @default.
• W3126149503 citedByCount "12" @default.
• W3126149503 countsByYear W31261495032021 @default.
• W3126149503 countsByYear W31261495032022 @default.
• W3126149503 countsByYear W31261495032023 @default.
• W3126149503 crossrefType "journal-article" @default.
• W3126149503 hasAuthorship W3126149503A5013341404 @default.
• W3126149503 hasAuthorship W3126149503A5014829112 @default.
• W3126149503 hasAuthorship W3126149503A5017334285 @default.
• W3126149503 hasAuthorship W3126149503A5028065894 @default.
• W3126149503 hasAuthorship W3126149503A5035724058 @default.
• W3126149503 hasAuthorship W3126149503A5039160380 @default.
• W3126149503 hasAuthorship W3126149503A5044080421 @default.
• W3126149503 hasAuthorship W3126149503A5045285437 @default.
• W3126149503 hasAuthorship W3126149503A5045899822 @default.
• W3126149503 hasAuthorship W3126149503A5055221542 @default.
• W3126149503 hasAuthorship W3126149503A5061545133 @default.
• W3126149503 hasAuthorship W3126149503A5065471639 @default.
• W3126149503 hasAuthorship W3126149503A5074756797 @default.
• W3126149503 hasAuthorship W3126149503A5076699095 @default.
• W3126149503 hasConcept C121608353 @default.
• W3126149503 hasConcept C126322002 @default.
• W3126149503 hasConcept C143998085 @default.
• W3126149503 hasConcept C197934379 @default.
• W3126149503 hasConcept C2776530083 @default.
• W3126149503 hasConcept C2776694085 @default.
• W3126149503 hasConcept C2777063308 @default.
• W3126149503 hasConcept C2778248108 @default.
• W3126149503 hasConcept C2778375690 @default.
• W3126149503 hasConcept C2779998722 @default.
• W3126149503 hasConcept C509974204 @default.
• W3126149503 hasConcept C526805850 @default.
• W3126149503 hasConcept C71924100 @default.
• W3126149503 hasConceptScore W3126149503C121608353 @default.
• W3126149503 hasConceptScore W3126149503C126322002 @default.
• W3126149503 hasConceptScore W3126149503C143998085 @default.
• W3126149503 hasConceptScore W3126149503C197934379 @default.
• W3126149503 hasConceptScore W3126149503C2776530083 @default.
• W3126149503 hasConceptScore W3126149503C2776694085 @default.
• W3126149503 hasConceptScore W3126149503C2777063308 @default.
• W3126149503 hasConceptScore W3126149503C2778248108 @default.
• W3126149503 hasConceptScore W3126149503C2778375690 @default.
• W3126149503 hasConceptScore W3126149503C2779998722 @default.
• W3126149503 hasConceptScore W3126149503C509974204 @default.
• W3126149503 hasConceptScore W3126149503C526805850 @default.
• W3126149503 hasConceptScore W3126149503C71924100 @default.
• W3126149503 hasFunder F4320307758 @default.
• W3126149503 hasLocation W31261495031 @default.
• W3126149503 hasOpenAccess W3126149503 @default.
• W3126149503 hasPrimaryLocation W31261495031 @default.
• W3126149503 hasRelatedWork W1919481286 @default.
• W3126149503 hasRelatedWork W1973308436 @default.

• next